Lipid-lowering therapy after acute coronary syndrome

E Pogran, AL Burger, D Zweiker, CC Kaufmann… - Journal of Clinical …, 2024 - mdpi.com
Achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets
remains a significant challenge in clinical practice. This review assesses the barriers to …

[HTML][HTML] Appropriateness of dyslipidemia management strategies in post-acute coronary syndrome: a 2023 update

F Lucà, F Oliva, CM Rao, MG Abrignani, AF Amico… - Metabolites, 2023 - mdpi.com
It has been consistently demonstrated that circulating lipids and particularly low-density
lipoprotein cholesterol (LDL-C) play a significant role in the development of coronary artery …

Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective …

G Nasso, C Larosa, F Bartolomucci… - Journal of Clinical …, 2024 - mdpi.com
Background. The in-hospital reduction in low-density lipoprotein cholesterol (LDL-C) levels
following acute coronary syndrome (ACS) is recommended in the current clinical guidelines …

Impact of an Intensive Lipid-Lowering Therapy Protocol on Achieving Target Low-Density Lipoprotein Cholesterol Levels in Patients With Acute Coronary Syndrome

K Seiyama, A Oka, T Miyoshi, Y Sudo, W Takagi… - Circulation …, 2025 - jstage.jst.go.jp
Background: Intensive lipid-lowering therapy (ILLT) is crucial for preventing secondary acute
coronary syndrome (ACS). However, achieving target low-density lipoprotein cholesterol …